DC Chemicals

All products / DC7178

JNJ-7706621
CAT. NO. DC7178

JNJ-7706621

Pack sizes and prices

Pack sizePrice
100 mg$550 USDRequest a quote →
250 mg$1,000 USDRequest a quote →
1 g$1,900 USDRequest a quote →

In stock. Contact our team for lead time, shipping and final quotation.

Product overview

JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9, 3, 11, and 15 nM for CDK1, CDK2, Aurora-A and Aurora-B, respectively.

For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.

Identity and specifications

Catalog numberDC7178
Product nameJNJ-7706621
CAS443797-96-4
Molecular formulaC15H12F2N6O3S
Molecular weight394.3560
Purity>98%
SMILESS(C1C([H])=C([H])C(=C([H])C=1[H])N([H])C1N=C(N([H])[H])N(C(C2C(=C([H])C([H])=C([H])C=2F)F)=O)N=1)(N([H])[H])(=O)=O

Source-listed specifications; the batch COA applies.

Source and product documents

The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.

DC Chemicals — JNJ-7706621 (DC7178)

Source references

[1]. Huang S, et al. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. Epub 2006 May 6. [2]. Matsuhashi A, et al. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012 Jul;12(6):625-39. [3]. Danhier F, et al. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm. 2010 Jun 15;392(1-2):20-8. [4]. Emanuel S, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65(19):9038-46.

Related research products